- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
Population: Infants (<1 year)
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Non-hospital health centre
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Metapneumovirus
- Parainfluenza Virus
- Rhinovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Adenovirus infection
- Metapneumovirus infection
- Parainfluenza virus infection
- Rhinovirus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Human metapneumovirus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Blood sample
- Nasopharyngeal swab
- Nasal lining fluid sample
- General population
- Infants (<1 year)
- Outpatient clinic
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Infants (<1 year)
- Children (1-11 years)
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Arboviral disease
- Vector-borne disease
- Blood sample
- Urine sample
- Hair
- Saliva
- Semen
- Vaginal fluids
- Adults (18-64 years)
- Elderly (≥65 years)
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Emergency department
- Arbovirus
- Chikungunya virus
- Vector-borne
- Dengue virus
- Zika virus
- West Nile virus
- Japanese encephalitis virus
- Arboviral disease
- Vector-borne disease
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir